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Introduction
Advanced Breast Cancer (ABC) comprises both locally advanced
(LABC) and metastatic breast cancer (MBC) [1]. Although treat-
able, MBC remains an incurable disease with a median overall
survival of 2–3 years and a 5-year survival of only25% [2–4].
Some more recent series seem to indicate an improvement in me-
dian overall survival [5, 6].
A recent comprehensive report [2] of the advances in this field
in the last decade shows that progress has been slow in terms of
improved outcomes, quality of life, awareness and information
regarding ABC.
The level of evidence used to base many recommendations re-
mains low, and more and better designed trials are needed to ad-
dress clinically important questions. An improved understanding
of the biology of ABC, its heterogeneity, and of the mechanisms
of resistance to the different types of therapies is being acquired
and it is anticipated that the application of new technologies,
such as next generation sequencing, patient xenographs, systems
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Table 1. Grading system [7]
Grade of recommendation/
description
Benefit versus risk and burdens Methodological quality of sup-
porting evidence
Implications
1A/Strong recommendation, high
quality evidence
Beneﬁts clearly outweigh risk and
burdens, or vice versa
RCTs without important limitations
or overwhelming evidence from
observational studies
Strong recommendation, can
apply to most patients in most
circumstances without
reservation
1B/Strong recommendation, mod-
erate quality evidence
Beneﬁts clearly outweigh risk and
burdens, or vice versa
RCTs with important limitations (in-
consistent results, methodological
ﬂaws, indirect, or imprecise) or ex-
ceptionally strong evidence from
observational studies
Strong recommendation, can
apply to most patients in most
circumstances without
reservation
1C/Strong recommendation, low
quality evidence
Beneﬁts clearly outweigh risk and
burdens, or vice versa
Observational studies or case series Strong recommendation, but may
change when higher quality evi-
dence becomes available
2A/Weak recommendation, high
quality evidence
Beneﬁts closely balanced with risks
and burden
RCTs without important limitations
or overwhelming evidence from
observational studies
Weak recommendation, best ac-
tion may differ depending on
circumstances or patients’ or so-
cietal values
2B/Weak recommendation, mod-
erate quality evidence
Beneﬁts closely balanced with risks
and burden
RCTs with important limitations (in-
consistent results, methodological
ﬂaws, indirect, or imprecise) or ex-
ceptionally strong evidence from
observational studies
Weak recommendation, best ac-
tion may differ depending on
circumstances or patients’ or so-
cietal values
2C/Weak recommendation, low
quality evidence
Beneﬁts closely balanced with risks
and burden
Observational studies or case series Very weak recommendation, other
alternatives may be equally
reasonable
SECTION I. GENERAL RECOMMENDATIONS
GUIDELINE STATEMENT LoE Consensus
The ABC community strongly calls for clinical trials addressing important unanswered clinical questions in this set-
ting, and not just for regulatory purposes. Clinical trials should continue to be performed, even after approval
of a new treatment, providing real world performance of the therapy.
Expert opinion Voters: 43
Yes: 100%
Every advanced breast cancer patient must have access to optimal cancer treatment and supportive care accord-
ing to the highest standards of patient centered care, as deﬁned by:
 Open communication between patients and their cancer care teams as a primary goal.
 Educating patients about treatment options and supportive care, through development and dissemination of
evidence-based information in a clear, culturally appropriate form.
 Encouraging patients to be proactive in their care and to share decision-making with their health care
providers.
 Empowering patients to develop the capability of improving their own quality of life within their cancer
experience.
 Always taking into account patient preferences, values and needs as essential to optimal cancer care.
Expert opinion Voters: 44
Yes: 100%
We strongly recommend the use of objective scales, such as the ESMO Magnitude of Clinical Beneﬁt Scale or the
ASCO Value Framework, to evaluate the real magnitude of beneﬁt provided by a new treatment and help pri-
oritize funding, particularly in countries with limited resources.
Expert opinion Voters: 40
Yes: 87.5% (35)
Abstain: 5% (2)
The use of telemedicine oncology to help management of patients with ABC living in remote places, is an import-
ant option to consider when geographic distances are a problem and provided that issues of connectivity are
solved.
Expert opinion Voters: 42
Yes: 92.8% (39)
Abstain: 4.7% (2)
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biology, and computer modelling, among others, will accelerate
advances.
Aiming at providing clinically oriented guidelines on how to
best manage ABC, the 3rd International Consensus Conference
for Advanced Breast Cancer (ABC 3) took place in Lisbon,
Portugal on November 5th–7th, 2015, bringing together over
1100 participants from 84 countries, including health profes-
sionals, patient advocates and journalists.
The ABC guidelines are developed as a joint effort from ESO
(European School of Oncology) and ESMO (European Society of
Medical Oncology), and are endorsed by EUSOMA (European
Society of Breast Cancer Specialists), ESTRO (European Society
of Radiation Oncology), UICC (Union for International Cancer
Control), SIS (Senologic International Society) and FLAM
(Federation LatinoAmericana de Mastologia). There was also of-
ficial representation of ASCO (American Society of Clinical
SECTION I Continued
GUIDELINE STATEMENT LoE Consensus
Strong consideration should be given to the use of validated PROMs (patient-reported outcome measures) for pa-
tients to record the symptoms of disease and side effects of treatment experienced as a regular part of clinical
care. These PROMs should be simple, and user-friendly to facilitate their use in clinical practice, and thought
needs to be given to the easiest collection platform, e.g. tablets or smartphones. Systematic monitoring would
facilitate communication between patients and their treatment teams by better characterizing the toxicities of
all anticancer therapies. This would permit early intervention of supportive care services enhancing quality of
life
1 C Voters: 39
Yes: 87.1% (34)
Abstain: 5.1% (2)
As survival is improving in many patients with ABC, consideration of survivorship issues should be part of the rou-
tine care of these patients. Health professionals should therefore be ready to change and adapt treatment strat-
egies to disease status, treatment adverse effects and quality of life, patients’ priorities and life plans.
Attention to chronic needs for home and family care, job and social requirements, should be incorporated in the
treatment planning and periodically updated.
Expert opinion Voters: 40
Yes: 95% (38)
Abstain: 5% (2)
ABC patients who desire to work or need to work for ﬁnancial reasons should have the opportunity to do so, with
needed and reasonable ﬂexibility in their working schedules to accommodate continuous treatment and hos-
pital visits.
Expert opinion Voters: 42
Yes: 100%
ABC patients with stable disease, being treated as a ‘chronic condition’, should have the option to undergo breast
reconstruction.
Expert opinion Voters: 39
Yes: 82% (32)
Abstain: 7.6% (3)
In ABC patients with long-standing stable disease, screening breast imaging should be an option. Expert opinion Voters: 40
Yes: 52.5% (21)
N: 47.5% (19)
Breast imaging should also be performed when there is a suspicion of loco-regional progression. Expert opinion Voters: 40
Yes: 100%
A biopsy (preferably providing histology) of a metastatic lesion should be performed, if easily accessible, to con-
ﬁrm diagnosis particularly when metastasis is diagnosed for the ﬁrst time.
1 B Voters: 43
Yes: 98% (42)
Biological markers (especially HR and HER-2) should be reassessed at least once in the metastatic setting, if clinic-
ally feasible. Depending on the metastatic site (e.g. bone tissue), technical considerations need to be discussed
with the pathologist.
1 B Voters: 44
Yes: 98% (43)
If the results of tumour biology in the metastatic lesion differ from the primary tumor, it is currently unknown
which result should be used for treatment-decision making. Since a clinical trial addressing this issue is difﬁcult
to undertake, we recommend considering the use of targeted therapy (ET and/or anti-HER-2 therapy) when re-
ceptors are positive in at least one biopsy, regardless of timing.
Expert Opinion 87%
To date, the removal of the primary tumor in patients with de novo stage IV breast cancer has not been associated
with prolongation of survival, with the possible exception of the subset of patients with bone only disease.
However, it can be considered in selected patients, particularly to improve quality of life, always taking into ac-
count the patient’s preferences. Of note, some studies suggest that surgery is only valuable if performed with the
same attention to detail (e.g. complete removal of the disease) as in patients with early stage disease.
Additional prospective clinical trials evaluating the value of this approach, the best candidates and best timing are
currently ongoing
2 B Voters: 44
Yes: 70.4% (31)
A small but very important subset of patients with ABC, for example those with oligo-metastatic disease or low vol-
ume metastatic disease that is highly sensitive to systemic therapy, can achieve complete remission and a long
survival.
A multimodal approach, including local-regional treatments with curative intent, should be considered for these
selected patients.
Expert opinion Voters: 43
Yes: 91% (39)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement.
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Table 2. Other ABC1 [10] and ABC2 [1] statements with only minor updates or with no updates
Recommendations LoE % Consensus
ABC IMPORTANT DEFINITIONS
VISCERAL CRISIS is deﬁned as severe organ dysfunction as assessed by signs and symptoms, laboratory studies,
and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies import-
ant visceral compromise leading to a clinical indication for a more rapidly efﬁcacious therapy, particularly since an-
other treatment option at progression will probably not be possible.
Expert opinion 95
PRIMARY ENDOCRINE RESISTANCE is deﬁned as: Relapse while on the ﬁrst 2 years of adjuvant ET, or PD within
ﬁrst 6 months of 1st line ET for MBC, while on ET.
SECONDARY (ACQUIRED) ENDOCRINE RESISTANCE is deﬁned as: Relapse while on adjuvant ET but after the ﬁrst
2 years, or Relapse within 12 months of completing adjuvant ET, or PD 6 months after initiating ET for MBC, while
on ET.
Note: resistance is a continuum and these deﬁnitions help mainly clinical trials and not necessarily clinical practice
Expert opinion 67
GENERAL STATEMENTS
The management of ABC is complex and, therefore, involvement of all appropriate specialties in a multidisciplinary
team (including but not restricted to medical, radiation, surgical oncologists, imaging experts, pathologists, gyne-
cologists, psycho-oncologists, social workers, nurses and palliative care specialists), is crucial.
Expert opinion 100
From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, supportive care, and
symptom-related interventions as a routine part of their care. The approach must be personalized to meet the
needs of the individual patient.
Expert opinion 100
Following a thorough assessment and conﬁrmation of MBC, the potential treatment goals of care should be dis-
cussed. Patients should be told that MBC is incurable but treatable, and that some patients can live with MBC for ex-
tended periods of time (many years in some circumstances).
This conversation should be conducted in accessible language, respecting patient privacy and cultural differences,
and whenever possible, written information should be provided.
Expert opinion 97
Patients (and their families, caregivers or support network, if the patient agrees) should be invited to participate in
the decision-making process at all times. When possible, patients should be encouraged to be accompanied by
persons who can support them and share treatment decisions (e.g. family members, caregivers, support network).
Expert opinion 100
There are few proven standards of care in ABC management. After appropriate informed consent, inclusion of pa-
tients in well-designed, prospective, independent trials must be a priority whenever such trials are available and
the patient is willing to participate.
Expert opinion 100
The medical community is aware of the problems raised by the cost of ABC treatment. Balanced decisions should
be made in all instances; patients’ well-being, length of life and preferences should always guide decisions.
Expert opinion 100
Specialized oncology nurses (if possible specialized breast nurses) should be part of the multidisciplinary team
managing ABC pts. In some countries this role may be played by a physician assistant or another trained and speci-
alized health care practitioner.
Expert opinion 92
All ABC patients should be offered comprehensive, culturally sensitive, up-to-date and easy to understand informa-
tion about their disease and its management.
1 B 97
The age of the patient should not be the sole reason to withhold effective therapy (in elderly patients) nor to over-
treat (in young patients). Age alone should not determine the intensity of treatment.
1 B 100
ASSESSMENT GUIDELINES
Minimal staging workup for MBC includes a history and physical examination, hematology and biochemistry tests,
and imaging of chest, abdomen and bone.
2 C 67
Brain imaging should not be routinely performed in asymptomatic patients. This approach is applicable to all pa-
tients with MBC including those patients with HER-2þ and/or TNBC MBC.
Expert opinion 94
The clinical value of tumor markers is not well established for diagnosis or follow-up after adjuvant therapy, but
their use is reasonable (if elevated) as an aid to evaluate response to treatment, particularly in patients with non-
measurable metastatic disease. A change in tumor markers alone should not be used to initiate a change in
treatment.
2 C 89
Evaluation of response to therapy should generally occur every 2–4 months for ET or after two to four cycles for CT,
depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of
treatment.
Imaging of target lesions may be sufﬁcient in many patients. In certain patients, such as those with indolent disease,
less frequent monitoring is acceptable.
Additional testing should be performed in a timely manner, irrespective of the planned intervals, if PD is suspected
or new symptoms appear. Thorough history and physical examination must always be performed.
Expert opinion 81
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Table 2 Continued
Recommendations LoE % Consensus
TREATMENT GENERAL GUIDELINES
Treatment choice should take into account at least these factors: HR and HER-2 status, previous therapies and tox-
icities, disease-free interval, tumour burden (deﬁned as number and site of metastases), biological age, perform-
ance status, co-morbidities (including organ dysfunctions), menopausal status (for ET), need for a rapid disease/
symptom control, socio-economic and psychological factors, available therapies in the patient’s country and pa-
tient preference.
Expert opinion 100
ER 1/HER-2 NEGATIVE ABC
Endocrine treatment after CT (maintenance ET) to maintain beneﬁt is a reasonable option, although this approach
has not been assessed in randomized trials.
1 C 88
Concomitant CTþET has not shown a survival beneﬁt and should not be performed outside of a clinical trial. 1 B 100
CHEMOTHERAPY AND BIOLOGICAL THERAPY
Both combination and sequential single agent CT are reasonable options. Based on the available data, we recom-
mend sequential monotherapy as the preferred choice for MBC. Combination CT should be reserved for patients
with rapid clinical progression, life-threatening visceral metastases, or need for rapid symptom and/or disease
control
1 B 96
In the absence of medical contraindications or patient concerns, anthracycline or taxane based regimens, prefer-
ably as single agents, would usually be considered as ﬁrst line CT for HER-2 negative MBC, in those patients who
have not received these regimens as (neo)adjuvant treatment and for whom chemotherapy is appropriate. Other
options are, however, available and effective, such as capecitabine and vinorelbine, particularly if avoiding alopecia
is a priority for the patient.
1 A 71
In patients with taxane-naive and anthracycline-resistant MBC or with anthracycline maximum cumulative dose or
toxicity (i.e. cardiac) who are being considered for further CT, taxane-based therapy, preferably as single agents,
would usually be considered as treatment of choice. Other options are, however, available and effective, such as
capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient.
1 A 59
In patients pre-treated (in the adjuvant and/or metastatic setting) with an anthracycline and a taxane, and who do
not need combination CT, single agent capecitabine, vinorelbine or eribulin are the preferred choices. Additional
choices include gemcitabine, platinum agents, taxanes, and liposomal anthracyclines. The decision should be indi-
vidualized and take into account different toxicity proﬁles, previous exposure, patient preferences, and country
availability.
1 B 77
If given in the adjuvant setting, a taxane can be re-used as 1st line therapy, particularly if there has been at least
1 year of disease-free survival.
1 A 92
Duration of each regimen and the number of regimens should be tailored to each individual patient. Expert opinion 96
Usually each regimen (except anthracyclines) should be given until progression of disease or unacceptable toxicity.
What is considered unacceptable should be deﬁned together with the patient.
1 B 72
OTHER AGENTS
Bevacizumab combined with a chemotherapy as 1st or 2nd line therapy for MBC provides only a moderate beneﬁt
in PFS and no beneﬁt in OS. The absence of known predictive factors for bevacizumab efﬁcacy renders recommen-
dations on its use difﬁcult. Bevacizumab can only therefore be considered as an option in selected cases in these
settings and is not recommended after 1st/2nd line.
1 A 74
SPECIFIC POPULATIONS: TREATMENT OF METASTATIC MALE MBC
For ERþ Male MBC, which represents the majority of the cases, ET is the preferred option, unless there is concern
or proof of endocrine resistance or rapidly progressive disease needing a fast response.
Expert opinion 100
For ERþ Male MBC tamoxifen is the preferred option. Expert opinion 83
For male patients with MBC who need to receive an AI, a concomitant LHRH agonist or orchidectomy is the pre-
ferred option. AI monotherapy may also be considered, with close monitoring of response.
Clinical trials are needed in this patient population.
Expert opinion 86
SPECIFIC SITES OF METASTASES
BONE METASTASES
Radiological assessments are required in patients with persistent and localized pain due to bone metastases to de-
termine whether there are impending or actual pathological fractures. If a fracture of a long bone is likely or has
occurred, an orthopaedic assessment is required as the treatment of choice may be surgical stabilization, which is
generally followed by RT. In the absence of a clear fracture risk, RT is the treatment of choice.
1 A 96
Neurological symptoms and signs which suggest the possibility of spinal cord compression must be investigated
as a matter of urgency. This requires a full radiological assessment of potentially affected area as well as adjacent
areas of the spine. MRI is the method of choice. An emergency surgical opinion (neurosurgical or orthopaedic) may
be required for surgical decompression. If no decompression/stabilization is feasible, emergency radiotherapy is
the treatment of choice and vertebroplasty is also an option.
1 B 100
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Table 2 Continued
Recommendations LoE % Consensus
BRAIN METASTASES
Patients with a single or small number of potentially resectable brain metastases should be treated with surgery or
radiosurgery. Radiosurgery is also an option for some unresectable brain metastases.
1 B 92
If surgery/radiosurgery is performed it may be followed by whole brain radiotherapy but this should be discussed
in detail with the patient, balancing the longer duration of intracranial disease control and the risk of neurocogni-
tive effects.
1 B 72
Because patients with HER2þve MBC and brain metastases can live for several years, consideration of long-term
toxicity is important and less toxic local therapy options (e.g. stereotactic RT) should be preferred to whole brain
RT, when available and appropriate (e.g. in the setting of a limited number of brain metastases).
1C 89
LIVER METASTASES
Prospective randomized clinical trials of local therapy for BC liver metastases are urgently needed, since available
evidence comes only from series in highly selected patients. Since there are no randomized data supporting the ef-
fect of local therapy on survival, every patient must be informed of this when discussing a potential local therapy
technique. Local therapy should only be proposed in very selected cases of good performance status, with limited
liver involvement, no extra-hepatic lesions, after adequate systemic therapy has demonstrated control of the dis-
ease. Currently, there are no data to select the best technique for the individual patient (surgery, stereotactic RT,
intra-hepatic CT. . .).
Expert opinion 83
MALIGNANT PLEURAL EFFUSIONS
Malignant pleural effusions require systemic treatment with/without local management. Thoracentesis for diagno-
sis should be performed if it is likely that this will change clinical management. False negative results are common.
Drainage is recommended in patients with symptomatic, clinically signiﬁcant pleural effusion. Use of an intrapleural
catheter or intrapleural administration of talc or drugs (e.g. bleomycin, biological response modiﬁers) can be help-
ful. Clinical trials evaluating the best technique are needed.
2B 86
CHEST WALL AND REGIONAL (NODAL) RECURRENCES
Due to the high risk of concomitant distant metastases, patients with chest wall or regional (nodal) recurrence
should undergo full restaging, including assessment of chest, abdomen and bone.
Expert opinion 100
Chest wall and regional recurrences should be treated with surgical excision when feasible with limited risk of
morbidity.
1 B 97
Locoregional radiotherapy is indicated for patients not previously irradiated. 1 B 97
For patients previously irradiated, re-irradiation of all or part of the chest wall may be considered in selected cases. Expert opinion 97
In addition to local therapy (surgery and/or RT), in the absence of distant metastases, the use of systemic therapy
(CT, ET and/or anti-HER-2 therapy) should be considered.
CT after ﬁrst local or regional recurrence improves long-term outcomes primarily in ER negative disease. ET in this
setting improves long-term outcomes for ER positive disease.
The choice of systemic treatment depends on tumor biology, previous treatments, length of disease free interval,
and patient-related factors (co-morbidities and preferences).
1 B 95
In patients with disease not amenable to radical local treatment, the choice of palliative systemic therapy should be
made according to principles previously deﬁned for metastatic BC.
These patients may still be considered for palliative local therapy.
Expert opinion 97
SUPPORTIVE AND PALLIATIVE CARE
Supportive care allowing safer and more tolerable delivery of appropriate treatments should always be part of the
treatment plan.
1 A 100
Early introduction of expert palliative care, including effective control of pain and other symptoms, should be a
priority.
1 A 100
Access to effective pain treatment (including morphine, which is inexpensive) is necessary for all patients in need
of pain relief.
1 A 100
Optimally, discussions about patient preferences at the end of life should begin early in the course of metastatic
disease. However, when active treatment no longer is able to control widespread and life-threatening disease, and
the toxicities of remaining options outweigh beneﬁts, physicians and other members of the healthcare team
should initiate discussions with the patient (and family members/friends, if the patient agrees) about end-of-life
care.
Expert
Opinion
96
ABC STATEMENTS FOR LABC (Note: For the purpose of these recommendations, LABC means inoperable, non-metastatic locally advanced
breast cancer)
Before starting any therapy, a core biopsy providing histology and biomarker (ER, PR, HER-2, proliferation/grade) ex-
pression is indispensable to guide treatment decisions.
1 B 97
1 B 100
Continued
Annals of Oncology Special article
Volume 28 | Issue 1 | 2017 doi:10.1093/annonc/mdw544 | 21
Downloaded from https://academic.oup.com/annonc/article-abstract/28/1/16/2660178
by Divisione Coordinamento Biblioteche Milano user
on 31 July 2018
Oncology) in the consensus panel. The ABC Conference was also
organized under the auspices of OECI (Organization of
European Cancer Institutes), and with the support of the BCRF
(Breast Cancer Research Foundation) and the Susan G Komen
for the Cure.
The present article summarizes the guidelines developed at
ABC3 and is supported with the level of evidence, the percentage
of consensus reached at the Conference, and supporting
references.
Methodology
Prior to the ABC 3 Conference, a set of preliminary recom-
mendation statements on the management of ABC were pre-
pared, based on available published data and following the
ESMO guidelines methodology. These recommendations were
circulated to all 44 panel members by email for comments and
corrections on content and wording. A final set of recommen-
dations was presented, discussed and voted upon during the
consensus session of ABC 3. All panel members were in-
structed to vote on all questions, with members with a poten-
tial conflict of interest or who did not feel comfortable
answering the question (e.g. due to lack of expertise in a par-
ticular field) instructed to vote ‘abstain’. Additional changes in
the wording of statements were made during the session. The
statements related to management of side effects and difficult
symptoms, included under the Supportive and Palliative care
section, were not voted on during the consensus session, but
discussed and unanimously agreed by email, and are con-
sidered to have 100% agreement.
Supplementary Table S1, available at Annals of Oncology on-
line, lists all members of the ABC 3 consensus panel and their
disclosures of any relationships with the pharmaceutical indus-
try that could be perceived as a potential conflict of interest.
Table 1 describes the grading system used [7]. ABC1 [10] and
ABC2 [1] statements with only minor updates or with no updates
are listed in Table 2.
General recommendations
The continuous increase in cancer care costs has inevitably led to
inequalities in access both between countries and within each
country. Cost, value and access are now central discussion points
and important factors in treatment-decision making. Both
ESMO and ASCO have put considerable effort into the develop-
ment of validated objective scales aiming at evaluating the real
magnitude of benefit provided by each new treatment, including
efficacy measures (e.g. impact on DFS, OS or PFS) and toxicity/
quality of life measures. The ESMO Magnitude of Clinical Benefit
Scale [8] and the ASCO Value Framework [9] are user-friendly
tools that can greatly assist decision-makers at the country and/or
hospital level in the difficult decisions regarding approval and
reimbursement.
Table 2 Continued
Recommendations LoE % Consensus
Since LABC patients have a signiﬁcant risk of metastatic disease, a full staging workup, including a complete history,
physical examination, lab tests and imaging of chest and abdomen (preferably CT) and bone, prior to initiation of
systemic therapy is highly recommended.
PET-CT, if available, may be used (instead of and not on top of CTs and bone scan). 2 B 100
Systemic therapy (not surgery or RT) should be the initial treatment.
If LABC remains inoperable after systemic therapy and eventual radiation, ‘palliative’ mastectomy should not be
done, unless the surgery is likely to result in an overall improvement in quality of life.
Expert opinion 100
A combined treatment modality based on a multidisciplinary approach (systemic therapy, surgery and radiother-
apy) is strongly indicated in the vast majority of cases.
1 A 100
For Triple Negative LABC, Anthracycline- and-taxane-based chemotherapy is recommended as initial treatment. 1 A 85
For HER-21 LABC, concurrent taxane and anti-HER-2 therapy is recommended since it increases the rate of pCR. 1 A 92
For HER-21 LABC, anthracycline-based chemotherapy should be incorporated in the treatment regimen. 1 A 72
When an anthracycline is given, it should be administered sequentially with the anti-HER-2 therapy. 1 A 87
Options for HR1 LABC include an anthracycline- and taxane-based chemotherapy regimen, or endocrine therapy. 1 A 85
The choice of CT versus ET, as initial treatment, will depend on tumor (grade, biomarker expression) and patient
(menopausal status, performance status, comorbidities, preference) considerations.
Expert
Opinion
85
Following effective neoadjuvant systemic therapy with or without radiotherapy, surgery will be possible in many
patients. This will consist of mastectomy with axillary dissection in the vast majority of cases, but in selected pa-
tients with a good response, breast conserving surgery may be possible.
2 B 98
INFLAMMATORY LABC
For inﬂammatory LABC, overall treatment recommendations are similar to those for non-inﬂammatory LABC, with
systemic therapy as ﬁrst treatment.
1 B 93
Mastectomy with axillary dissection is recommended in almost all cases, even when there is good response to pri-
mary systemic therapy.
I B 95
Immediate reconstruction is generally not recommended in patients with inﬂammatory LABC. Expert opinion 95
Loco-regional radiotherapy (chest wall and lymph nodes) is required, even when a pCR is achieved with systemic
therapy.
1 B 98
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The ABC3 experts also emphasize the responsibility of the aca-
demic and medical communities to advance the knowledge on
breast cancer and other relevant unanswered issues, by involve-
ment in clinical research aimed at addressing important clinical
questions, and not only in studies conducted for regulatory
purposes.
The importance of providing patients with full information
in appropriate, understandable and culturally sensitive way, as
well as involving them in sharing the decision-making regard-
ing all aspects of their management has been repeatedly stressed
in all ABC guidelines [1, 10]. A high standard of patient centred
care includes the following elements: appropriate information,
good communication with health professionals, patient educa-
tion, proactive advocacy, sensitivity to the patient’s prefer-
ences, values and needs, and providing patients with the
capabilities to improve their own quality of life [11].
Although the overall survival of ABC has remained stable, for
some subtypes, and in particular HER-2-positive metastatic
breast cancer, prolonged survival, well beyond the median 2–
3 years, has become a frequent reality. For these long-term sur-
vivors, survivorship issues which are specific for advanced cancer
patients, have emerged and need appropriate attention, research
and management. Work-related issues are central and solutions
not easy to implement. A recently published survey [12], found
that approximately half of the women in employment had to
change their work situation due to ABC and that 37% of them
had to give up work temporarily or permanently. Due to these in-
come problems and those related to the cost of care, the same sur-
vey found that 56% of ABC patients experienced a decline in
household income as a result of their disease. The ABC commu-
nity strongly advocates for the right of ABC patients to return or
maintain their work, since a substantial proportion of these pa-
tients are in their most productive years. Furthermore, in some
countries, health coverage is dependent on being employed. For
that to occur, we need flexibility of working schedules, new com-
munication technologies and home-based work which the ABC
community supports. In many countries this may imply a change
in the current labour-related laws.
Survivorship issues also include the potential discussion of
breast reconstruction, in those cases where the metastatic disease
is either in complete remission or in a durable stable situation.
No consensus could be reached regarding the use of breast imag-
ing to follow-up the unaffected breast, but the experts agreed that
imaging should be performed in case of suspicion of disease pro-
gression in the breast.
Regarding the need to biopsy metastatic disease and re-evaluate
the common biomarkers, the ABC recommendations had only
minor changes. There are situations where the need for a biopsy in
the metastatic setting is very clear, such as single lesions, history of
two or more malignancies, suspicion of benign histology or doubt
between progression or post-treatment necrosis. There is also con-
sensus regarding the importance of such biopsy in situations where
when a change in biomarkers would impact the treatment choice,
which would mainly occur when biomarkers were negative in the
primary tumor. There is some controversy about the benefits of a
biopsy in situations where there is no doubt about the nature of
the lesion(s) and where all receptors were positive in the primary
tumor, since the clinical implementation of new technologies such
as next generation sequencing for management decision-making s
not yet validated. However, the exact nature of a lesion is hard to
ascertain without the confirmation by a biopsy as shown in some
retrospective and prospective studies [13–15]. There is also an
undisputable importance of collection of material for research
purposes, both ongoing and future.
Technical issues should be discussed with the breast patholo-
gist, in particular in case of bone biopsies with the inherent decal-
cification problems, which may interfere with the biomarker
analysis [16, 17], as experienced in Safir01/UNICANCER trial
[18]. For that reason, decalcification using EDTA is recom-
mended for bone biopsies, when it is the only metastatic site [17].
Adding to the complexity of this issue is the fact that negative bio-
marker results may limit the eligibility for reimbursement of
therapies dedicated to specific subtypes, in some countries.
A number of prospective randomized trials have assessed or are
assessing the role of removing the primary tumor in patients with
de novo metastatic disease. So far only two small studies have been
published/presented [19, 20]. A subgroup analysis of the Turkish
study suggested a potential benefit in patients with ER/PgRþ,
HER-2 negative, solitary bone metastasis, who are younger than 55
years of age, while patients with multiple pulmonary and liver me-
tastasis did worse with an overall 3-year survival of 31% in the sur-
gery group versus 67% for the systemic therapy group [20]. In the
Indian trial, a decrease in distant progression-free survival was
observed in patients allocated to surgery. Results of larger, pro-
spective studies are awaited. Until then, the recommendation is to
discuss surgery on a case-by-case basis and importantly, only
SECTION 2. ABC IMPORTANT DEFINITIONS
GUIDELINE STATEMENT LoE Consensus
OLIGO-METASTATIC DISEASE is deﬁned as low volume metastatic disease with limited number and size of
metastatic lesions (up to ﬁve and not necessarily in the same organ), potentially amenable for local treat-
ment, aimed at achieving a complete remission status.
Expert opinion Voters: 36
Yes: 78% (28)
Abstain: 6% (2)
PATIENTS WITH MULTIPLE CHRONIC CONDITIONS are deﬁned as patients with additional comorbidities
(e.g. cardiovascular, impaired renal or liver function, autoimmune disease) making it difﬁcult to account for
all of the possible extrapolations to develop speciﬁc recommendations for care.
Expert opinion Voters: 42
Yes:100%
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement.
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SECTION 3. HER-2 POSITIVE ABC
GUIDELINE STATEMENT LoE Consensus
Anti-HER-2 therapy should be offered early (as 1st line) to all patients with HER-2þ ABC, except in the pres-
ence of contra-indications to the use of such therapy
1 A Voters: 43
Yes: 98% (42)
For highly selected patients* with ERþ/HER-2þ MBC, for whom ET is chosen over CT, ET should be given in
combination with anti-HER-2 therapy (either trastuzumab or lapatinib) since the combination provides PFS
beneﬁt (i.e. ‘time without CT’) compared to ET alone. The addition of anti-HER-2 therapy to ET in the 1st line
setting has not led to a survival beneﬁt but long-term follow-up was not collected in the available trials. In
addition, this strategy is currently being directly compared with CTþanti-HER2 therapy. (*see deﬁnition in
text)
1 A Voters: 43
Yes: 72% (31)
Abstain: 9% (4)
For patients with ERþ/HER-2þ MBC, for whom CTþanti-HER2 therapy was chosen as 1st line therapy and pro-
vided a beneﬁt, it is reasonable to use ETþanti-HER2 therapy as maintenance therapy, after stopping CT, al-
though this strategy has not been studied in randomized trials.
1 C Voters: 39
Yes: 79% (31)
Abstain: 10% (4)
Patients progressing on an anti-HER-2 therapy combined with a cytotoxic or endocrine agent should be
offered additional anti-HER-2 therapy with subsequent treatment since it is beneﬁcial to continue suppres-
sion of the HER-2 pathway. The optimal duration of anti-HER-2 therapy for MBC (i.e. when to stop these
agents) is currently unknown.
1 B Voters: 43
Yes: 91% (39)
Abstain: 7% (3)
In patients achieving a complete remission, the optimal duration of maintenance anti-HER2 therapy is un-
known and needs to be balanced against treatment toxicity, logistical burden and cost. Stopping anti-HER2
therapy after several years of sustained complete remission may be considered in some patients, particu-
larly if treatment re-challenge is available in case of progression.
Expert Opinion Voters: 42
Yes: 93% (39)
No: 7% (3)
Patients who have received any type of (neo)adjuvant anti-HER-2 therapy should not be excluded from clinical
trials for HER-2þ MBC. These patients remain candidates for anti-HER-2 therapies.
1 B Voters: 40
Yes: 100%
In the 1st line setting, for HER-2þ MBC previously treated (in the adjuvant setting with DFI >12 months) or un-
treated with trastuzumab, combinations of CTþtrastuzumab are superior to combinations of CTþlapatinib
in terms of PFS and OS.
1 A Voters: 44
Yes: 95% (42)
Abstain: 5% (2)
The standard 1st line therapy for patients previously untreated with anti-HER-2 therapy is the combination of
CTþtrastuzumab and pertuzumab, because it has proven to be superior to CTþtrastuzumab in terms of OS
in this population.
1 A Voters: 42
Yes: 86% (36)
Abstain: 12% (5)
For patients previously treated (in the (neo)adjuvant setting) with anti-HER-2 therapy, the combination of
CTþtrastuzumab and pertuzumab is an important option for 1st line therapy. Few (88) of these patients
were treated in the Cleopatra trial and all with trastuzumab-free interval >12 months.
1 A Voters: 41
Yes: 76% (31)
Abstain: 22% (9)
There are currently no data supporting the use of dual blockade with trastuzumabþpertuzumab and CT be-
yond progression (i.e. continuing dual blockade beyond progression) and therefore this 3 drug regimen
should not be given beyond progression outside clinical trials.
1 A (against its use) Voters: 43
Yes: 86% (37)
Abstain: 9% (4)
In a HER-2þ MBC patient, previously untreated with the combination of CTþtrastuzumabþpertuzumab, it is
acceptable to use this treatment after 1st line.
Expert Opinion Voters: 37
Yes: 76% (28)
Abstain: 16% (6)
After 1st line trastuzumab-based therapy, T-DM1 provides superior efﬁcacy relative to other HER-2-based thera-
pies in the 2nd line (versus lapatinibþcapecitabine) and beyond (versus treatment of physician’s choice).
T-DM1 should be preferred in patients who have progressed through at least 1 line of trastuzumab-based ther-
apy, because it provides an OS beneﬁt.
However, there are no data on the use of T-DM1 after dual blockade with trastuzumabþpertuzumab.
1 A Voters: 42
Yes: 88% (37)
Abstain: 129% (5)
In case of progression on trastuzumab-based therapy, the combination trastuzumabþlapatinib is a reasonable
treatment option for some patients. There are however, no data on the use of this combination after pro-
gression on pertuzumab or T-DM1.
1 B Voters: 43
Yes: 84% (36)
Abstain: 12% (5)
All patients with HER-2þ MBC who relapse after adjuvant or any line metastatic anti-HER-2 therapy should be
considered for further anti-HER-2 therapy, except in the presence of contraindications. The choice of the
anti-HER-2 agent will depend on country-speciﬁc availability, the speciﬁc anti-HER-2 therapy previously ad-
ministered, and the relapse free interval. The optimal sequence of all available anti-HER-2 therapies is cur-
rently unknown.
1 B Voters: 40
Yes: 86% (36)
Abstain: 12.5% (5)
Regarding the CT component of HER-2 positive MBC treatment:
When pertuzumab is not given, 1st line regimens for HER-2 MBC can include trastuzumab combined with
vinorelbine or a taxane. Differences in toxicity between these regimens should be considered and discussed
with the patient in making a ﬁnal decision.
Other CT agents can be administered with trastuzumab but are not as well studied and are not preferred.
1 A Voters: 41
Yes: 88% (36)
Abstain: 10% (4)
For later lines of therapy, trastuzumab can be administered with several CT agents, including but not limited
to, vinorelbine (if not given in 1st line), taxanes (if not given in 1st line), capecitabine, eribulin, liposomal
2 A Voters: 43
Yes: 91% (39)
Continued
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consider surgery if it can be performed with a high quality proced-
ure [21].
The definition of oligometastatic disease (see next section) has
been enlarged to encompass low volume metastatic disease, i.e.
limited number and size of metastatic lesions (up to five and not
necessarily in the same organ) and potentially amenable for local
treatment which is aimed at achieving a complete remission. The
development of minimally invasive surgical techniques and
highly conformal ablative radiotherapy allow for safe and effect-
ive ablation of metastatic lesions in most locations. Although
some retrospective studies have suggested that achieving a sus-
tained complete remission seems to be associated with a longer
survival [22], the true impact of these local-regional therapies on
long-term outcome remains unknown, and prospective and if
possible randomized trials are needed.
ABC important definitions
Most clinical situations occur as a continuum and dividing them
into categories of stage, grade, risk group, or other factors is al-
ways artificial and based on oversimplification of thresholds.
Such a categorization is, however, useful to guide treatment
choices, to help assure adherence to guidelines and recommenda-
tions, and to facilitate clinical research. Following the effort of
previous editions, ABC provides two additional definitions: ‘oli-
gometastatic disease’ discussed above and the complex clinical
situation of ‘multiple chronic conditions’. The latter is becoming
increasingly important and more frequent in view of the aging of
the population in general and of cancer patients in particular.
Managing advanced cancer, the consequences of the disease and
of the rapidly increasing number and type of pharmacologic and
non-pharmacologic interventions in patients with several coex-
isting conditions is a major challenge. Furthermore, these pa-
tients are systematically excluded from clinical trials and hence
available data, in particular regarding the use of new agents in
these situations, are scarce and eagerly needed.
HER-2 positive ABC
Among all breast cancer subtypes, HER2-positive ABC has had
the largest progress over the last decade. The introduction of new
anti-HER2 therapies, such as pertuzumab and T-DM1 [23–27],
was a significant step forward but also created a number of new
uncertainties related to optimal combination/sequence of all
available treatments.
In view of the overall survival (OS) results obtained with most
combinations of chemotherapy plus anti-HER-2 agents, the role
of endocrine therapy plus anti-HER-2 agents for the subgroup of
patients with ERþ/HER-2þ disease has been questioned.
Although published studies have not demonstrated an OS benefit
of this combination, long-term data were not collected in these
trials. Of note, the OS analysis of the TAnDEM trial, excluding
patients who crossed over to trastuzumab, demonstrated a bor-
derline OS benefit for the combination arm [28]. In the absence
of valuable biomarkers, this approach should be reserved for
highly selected patients, including those with contraindications
to chemotherapy, patient’s with a strong preference against
chemotherapy or those with a long disease-free interval, minimal
disease burden, in particular in terms of visceral involvement,
and/or strong ER/PgR expression. Trials directly comparing
chemotherapy plus anti-HER2 therapy versus endocrine therapy
plus anti-HER2 therapy are currently ongoing (Detect
V/CHEVENDO (NCT02344472), SYSUCC-002 (NCT01950182)
and PERNETTA trials) and their results will allow for better
recommendations. In addition, in several countries anti-HER2
therapy, namely trastuzumab, can only be used once in the meta-
static setting since its use beyond progression is either not
approved or not reimbursed; in those cases, preference should be
given to a combination of chemotherapy plus anti-HER-2
therapy.
The combination of endocrine therapy plus anti-HER2 therapy
is particularly useful as maintenance therapy for ERþ/
HER2þABC, after initial cycles of chemotherapy plus anti-HER-
2 therapy. Despite the absence of randomized trials, clinical
SECTION 3 Continued
GUIDELINE STATEMENT LoE Consensus
anthracyclines, platinum, gemcitabine, or metronomic CM. The decision should be individualized and take
into account different toxicity proﬁles, previous exposure, patient preferences, and country availability.
Abstain: 9% (4)
CT agents to combine with a dual blockade of trastuzumabþpertuzumab are docetaxel (LoE: 1A) or paclitaxel
(LoE: 1B). Also possible are vinorelbine (LoE: 2 A), nab-paclitaxel (LoE: 2B) and capecitabine (LoE: 2A).
See in statement Voters: 43
Yes: 86% (37)
Abstain: 11.6% (5)
HER-21 ABC and BRAIN METASTASES
In patients with HER-2-positive ABC with brain metastases and stable extracranial disease, systemic therapy
should not be changed.
1 C Voters: 42
Yes: 95% (40)
Abstain: 5% (2)
For patients with HER-2-positive cancers where brain metastases are the only site of recurrence, the addition
of CT to local therapy is not known to alter the course of the disease. It is recommended to re-start the
anti-HER-2 therapy (trastuzumab) if this had been stopped.
1 C Voters: 42
Y: 83% (35)
A: 7% (3)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; ET, endocrine therapy; CT, chemotherapy;
DFI, disease-free interval, CM, cyclophosphamide þmethotrexate.
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experience and low toxicity (in particular if trastuzumab is used),
makes this a reasonable option, most probably delaying disease
progression and the consequent need for chemotherapy.
The issue of duration of anti-HER-2 therapy in the metastatic
setting is of crucial importance, in view of the potential benefits
as well as the substantial costs associated with these agents. There
are sufficient data [29, 30] to recommend continuing trastuzu-
mab beyond progression, but the optimal duration of this treat-
ment and how many lines beyond progression should it be used is
currently unknown. Data are very scarce related to the use beyond
progression of other anti-HER2 agents and no data exist support-
ing the use of dual blockade beyond progression.
SECTION 4. ER POSITIVE/HER-2 NEGATIVE (LUMINAL) ABC
GUIDELINE STATEMENT LoE Consensus
Endocrine therapy (ET) is the preferred option for hormone receptor positive disease, even in the presence of
visceral disease, unless there is visceral crisis or concern/proof of endocrine resistance.
1 A Voters: 41
Yes: 93% (38)
Abstain: 7% (3)
The preferred 1st line ET for postmenopausal patients depends on type and duration of adjuvant ET as well as
time elapsed from the end of adjuvant ET; it can be an aromatase inhibitor, tamoxifen or fulvestrant.
1 A Voters: 44
Yes: 84% (37)
Abstain: 7% (3)
The combination of a nonsteroidal AI and fulvestrant as ﬁrst-line therapy for postmenopausal patients resulted
in signiﬁcant improvement in both PFS and OS compared to AI alone in one phase III trial and no beneﬁt in
a second trial with a similar design. Subset analysis suggested that the beneﬁt was limited to patients with-
out prior exposure to adjuvant ET (tamoxifen). Based on these data, combination ET may be offered to
some patients with MBC without prior exposure to adjuvant ET.
2 B Voters: 43
Yes: 33% (14)
No: 53% (23)
Abstain: 14% (6)
The addition of everolimus to an AI is a valid option for some postmenopausal patients with disease progres-
sion after a non-steroidal AI, since it signiﬁcantly prolongs PFS, albeit without OS beneﬁt. The decision to treat
must take into account the individual relevant toxicities associated with this combination and should be
made on a case by case basis.
Tamoxifen can also be combined with everolimus.
1 B
2 B
Voters: 40
Yes: 84% (34)
Abstain: 13% (5)
The addition of the CDK4/6 inhibitor palbociclib to an aromatase inhibitor, as 1st line therapy, for postmeno-
pausal patients (except patients relapsing <12 months from the end of adjuvant AI), provided a signiﬁcant im-
provement in PFS (10 months), with an acceptable toxicity proﬁle, and is therefore one of the preferred
treatment options, where available. OS results are still awaited.
ESMO MCBS: 3*
1 A Voters: 37
Yes: 92% (34)
Abstain: 3% (1)
The addition of CDK4/6 inhibitor palbociclib to Fulvestrant, beyond 1st line therapy, for pre/peri/postmeno-
pausal patients, provided signiﬁcant improvement in PFS (5 months) as well as improvement of QoL, and is
a treatment option. OS results are awaited.
For pre/peri-menopausal pts, an LHRH-agonist must also be used.
At present, no predictive biomarker other than hormone receptor status exists to identify patients who will
beneﬁt from these type of agents and research efforts must continue.
ESMO MCBS: 4*
1 A Voters: 42
Yes: 86% (36)
Abstain: 10% (4)
The optimal sequence of endocrine agents after 1st line ET is uncertain. It depends on which agents were used
in the (neo)adjuvant and 1st line ABC settings. Available options include AI, tamoxifen, fulvestrantþpalbociclib,
AIþeverolimus, tamoxifenþeverolimus, fulvestrant, megestrol acetate and estradiol.
It is currently unknown how the different combinations of endocrineþbiological agents compare with each
other, and with single agent CT. Several trials are ongoing.
1 A Voters: 40
Yes: 93% (37)
Abstain: 5% (2)
For pre-menopausal women, for whom ET was decided, ovarian suppression/ablation combined with add-
itional endocrine therapy is the preferred choice.
1 B Voters: 43
Yes: 93% (40)
Abstain: 5% (2)
Ovarian ablation by laparoscopic bilateral oophorectomy ensures deﬁnitive estrogen suppression and contra-
ception, avoids potential initial tumor ﬂare with LHRH agonist, and may increase eligibility for clinical trials.
Patients should be informed on the options of OS/OA and decision should be made on a case by case.
Expert Opinion Voters: 43
Yes: 91% (39)
Abstain: 7% (3)
For pre-menopausal women, the additional endocrine agent can be AI or tamoxifen, according to type and
duration of prior adjuvant endocrine therapy but AI absolutely mandates the use of ovarian suppression/
ablation.
Fulvestrant is also a valuable option, but for the moment also mandates the use of ovarian suppression/
ablation.
1 B
1 C
Voters: 42
Y: 95% (40)
Abstain: 5% (2)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; ET, endocrine therapy; CT, chemotherapy;
QoL, quality-of-life.
ESMO MBCS¼ ESMO Magnitude of Clinical Beneﬁt Scale; *5 very important explanation in text.
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A particularly difficult situation, albeit also a fortunate one, re-
lates to the optimal duration of trastuzumab therapy in patients
achieving long-term complete remission. This needs to be bal-
anced against toxicity, logistical burden and cost. Currently no
data exist to support therapeutic decisions in this setting, and the
panel supported a cautious statement approving consideration of
stopping trastuzumab in these circumstances in some patients,
particularly if treatment re-challenge is available in case of pro-
gression, which is not the case in all countries.
Dual blockade with trastuzumab and pertuzumab in combin-
ation with chemotherapy as 1st line therapy, provides substantial
benefit in terms of OS and PFS [23]. It is therefore considered by
the panel as the standard of care for patients previously untreated
with trastuzumab, in the (neo)adjuvant setting, and an important
treatment option for patients previously treated with trastuzu-
mab. The difference in the strength of recommendation is due to
the fact that very few patients (only 88) who were previously
treated with trastuzumab were enrolled in the Cleopatra trial. In
addition, in the Marianne trial [26] the dual blockade strategy
did not prove to be superior to chemotherapy and trastuzumab,
albeit with a different combination of agents—T-DM1 and
Pertuzumab. The reasons for this lack of benefit are currently un-
known and could be related to the different patient populations
enrolled in both trials (more (30%) patients in Marianne had
been previously treated with trastuzumab), the choice of agents
with the presence or absence of synergistic effects, the absence of
standard chemotherapy agents (DM1 being a cytotoxic agent not
used as single agent) or other factors.
After the discussion and voting during ABC3, the Pherexa [27]
study was presented, evaluating the role of dual blockade with
trastuzumabþ pertuzumabþ capecitabine for patients previ-
ously treated with a taxane and trastuzumab in the metastatic set-
ting. Surprisingly, a non-significant benefit of only 2 months was
seen in the primary endpoint PFS, while an 8-month benefit was
observed in OS albeit non-statistically significant (in view of the
lack of significant PFS benefit).
Many questions remain unanswered in the management of
HER-2þABC. We have no data on the role of dual blockade for
patients relapsing during and within 12 months of adjuvant tras-
tuzumab, since these patients have been excluded from clinical
trials. This aggressive situation is a clear unmet need for which
data must be generated. Following the approval, both by FDA
and EMA, of pertuzumab use in the neoadjuvant setting, there is
an urgent need to evaluate the best treatment options for the
patients who relapse after receiving chemother-
apyþ trastuzumabþ pertuzumab in the early setting. It is also
currently unknown how trastuzumabþ pertuzumabþ chemo-
therapy compares to T-DM1, as 1st or later lines of therapy. We
also have no data on the best treatment option after progression
on dual blockade with pertuzumabþ trastuzumab, namely how
T-DM1 performs in this setting.
While trastuzumabþ lapatinib (without chemotherapy) is a
valuable option for some patients, after progression on chemo-
therapyþ trastuzumab, there are no data on the use of this com-
bination after progression on pertuzumab or T-DM1.
All these unanswered questions and the definition of the best
sequence of therapies for the individual patient may prove dif-
ficult to evaluate in prospective, randomized trials, with the
absence of specific biomarkers. In this scenario, registry
studies, such as the SystHERs Registry Study [31] and
registHER, as well as collection of treatment and outcome data
beyond progression in all HER-2-positive ABC clinical trials,
are of great importance.
In ABC3, the optimal chemotherapy component for the
treatment of HER-2þ disease was discussed. The panel has
stressed the importance of treatment decisions that are based
not only on efficacy, but also on toxicity profile, and patients’
preferences.
For 1st line therapy, when trastuzumab is used as sole anti-
Her2 agent, the preferred agents are vinorelbine or a taxane.
Importantly, single agent vinorelbine in association with trastu-
zumab has shown superior or equal efficacy compared to either
paclitaxel or docetaxel, in the TRAVIOTA and HERNATA trials,
and has a better tolerability [32, 33]. For later lines of therapy,
trastuzumab can be administered with almost all chemotherapy
agents, including but not limited to, vinorelbine (if not given in
1st line), taxanes (if not given in 1st line), capecitabine, eribulin,
liposomal anthracyclines, platinum, gemcitabine, or metronomic
CM (low dose, oral, cyclophosphamide and methotrexate). The
decision should be individualized and take into account different
toxicity profiles, previous exposure, patient preferences, and
country availability. Combinations of other anti-HER2 agents,
namely TKIs, with chemotherapy are more limited due to tox-
icity. There are currently no data to decide on the best sequence
for each individual patient.
When dual blockade with trastuzumab and pertuzumab is
used, possible agents to combine are docetaxel [23], weekly pacli-
taxel [34], vinorelbine [35] and nab-paclitaxel [36]. After the vot-
ing that took place in ABC3, the Pherexa trial [27], presented at
ASCO 2016, provided some evidence regarding the combination
of dual blockade with capecitabine.
ER positive/HER-2 negative (luminal) ABC
One of the most important recommendations relates to the pre-
ferred treatment for luminal ABC, which should be endocrine
therapy in the majority of cases, excluding those with visceral cri-
sis and concern or proof of endocrine resistance. All breast cancer
guidelines concur with this recommendation but unfortunately
real life data studies show that most of these patients still receive
chemotherapy as their first treatment, despite the lower efficacy
[37].
Visceral crisis and endocrine resistance have been defined dur-
ing ABC 2 and published [1]. However, better predictive factors
are urgently needed to clearly identify those patients whose
tumors have primary endocrine resistance and are responsible for
the early and rapid progression seen in20–25% of luminal ABC
patients treated with endocrine therapy [38]. Possible reasons
may include ER loss [39] or ER mutations [40].
The most important advance in the management of luminal
ABC over the last 2 years has undoubtedly been the introduction
of a new class of agents, the CDK4/6 inhibitors, in combination
with an endocrine agent.
The value of the CDK4/6 inhibitor palbociclib, combined with
an aromatase inhibitor as 1st line therapy was evaluated initially
in a randomized phase II study, the PALOMA 1 trial [41], which
showed a substantial 10-month benefit in progression-free-
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survival (PFS) coupled with a favorable toxicity profile (main
toxicity being neutropenia). Based on these results, FDA granted
accelerated approval, which resulted in the drug being commer-
cially available in USA. At the 2016 ASCO meeting, the phase III
PALOMA 2 trial was presented and confirmed the 10-month
benefit in PFS, with the main toxicities being hematological
(mainly neutropenia) and fatigue [41]. OS results are still
awaited. In view of these results, the initial statement developed
at ABC3 was modified and re-voted by email and considers this
option as one of the preferred treatment options, where available.
Very recently (September 2016) EMA also started the approval
process of Palbociclib. However, its approval/reimbursement in
all individual countries is still pending and the issue of cost is of
crucial importance for its implementation in clinical practice, as
it is for many targeted agents namely anti-HER-2 agents.
Beyond 1st line endocrine therapy, addition of palbociclib to
fulvestrant resulted in significant albeit lower 5-month PFS pro-
longation in the PALOMA 3 phase III trial [42]. The quality of
life substudy has shown both an overall improvement and a
delayed deterioration of this important endpoint, with greater
improvement in baseline pain, in the palbociclib arm [43].
Importantly, the PALOMA-3 study accrued both postmeno-
pausal and pre/perimenopausal (in combination with ovarian
function suppression) patients, allowing for assessment of the
drug efficacy in a breast cancer population usually excluded from
ABC endocrine therapy trials. OS results are still awaited. In view
of available results, the ABC panel considers this as a treatment
option, where available.
The ESMO Magnitude of Clinical Benefit Scale (MCBS) was
calculated for the recently approved Palbociclib, for use in 1st
line and in 2nd line. As a reminder, the MCBS scores a given
treatment in a given setting, and based on published trials. At the
time of publishing the ABC3 guidelines, PALOMA 2 main results
and the accompanying quality of life substudy have been pre-
sented but not yet published. For this reason, the MCBS for the
use of palbociclib in 1st line was calculated using the PALOMA 1
trial efficacy data, which scores a 3 for efficacy. Once the
PALOMA 2 data is published the MCBS will be updated an e-up-
date made available through the ESMO guidelines website. For
the use of palbociclib as 2nd line therapy, data from PALOMA 3,
both efficacy and quality of life, were used. The MCBS was 3 for
efficacy, and due to the improvement in quality of life upgraded
to 4, which is the final score for this setting.
Another possible therapy is the combination of endocrine ther-
apy with the mTOR inhibitor, everolimus. This combination has
shown a PFS benefit of 6 months, without a significant OS
benefit, and with significant toxicity [44, 45]. However, as with
many agents, as more experience is gained regarding the use of
everolimus and the management of its toxicities, its clinical use
becomes easier. In addition, patient education is fundamental for
prevention and early management of associated side effects. Of
particular attention is the possibility of an excess mortality of this
combination in elderly patients (>70 years of age) [44, 46].
Currently, and in spite of intensive research, no predictive bio-
marker, other than hormone receptor status, exists to identify pa-
tients who will benefit the most from either m-TOR or CDK4-6
inhibitors and research efforts must continue.
The panel did not support (53.4% against) the 1st line combin-
ation of non-steroidal aromatase inhibitor and fulvestrant based
on the results of the SWOG S0226 trial [47]. There may be a bene-
fit for the minority of postmenopausal patients who are endo-
crine-naı¨ve.
The definition of the best 1st line approach for postmeno-
pausal patients will soon have additional data through the phase
III FALCON data that will be presented this year.
The optimal sequence of single endocrine agents and combin-
ations with targeted agents is currently unknown and is a research
priority. It is crucial to collect data from clinical trials beyond
progression to better understand the efficacy of each class of agent
when given after the other (e.g. CDK4-6 inhibitors after m-TOR
inhibitors and vice-versa).
Triple negative ABC
The treatment of triple-negative breast cancer (TN-ABC) still re-
mains the largest unmet need within ABC. In spite of extensive re-
search, no treatments apart from chemotherapy have so far proven
to be effective for this population. For this reason, no specific recom-
mendations can be made for this ABC subtype, with the possible ex-
ception of platinum compounds for BRCA-mutated patients.
Probably the largest achievement of the last 2 years was the
TNT study, comparing ‘standard’ docetaxel to carboplatin in
unselected TNBC patients (with pre-specified subgroup analysis
of BRCA-mutation carriers). The superiority of carboplatin was
demonstrated only among BRCA-positive patients, while in the
SECTION 5. TRIPLE NEGATIVE ABC
GUIDELINE STATEMENT LoE Consensus
For non-BRCA-associated triple negative ABC, there are no data supporting different or speciﬁc CT recommen-
dations. Therefore, all CT recommendations for HER-2 negative disease also apply for triple negative ABC.
1 A Voters: 44
Yes: 98% (43)
Abstain: 2% (1)
In triple-negative ABC patients (regardless of BRCA status), previously treated with anthracyclines with or with-
out taxanes in the (neo)adjuvant setting, carboplatin demonstrated comparable efﬁcacy and a more favor-
able toxicity proﬁle, compared to docetaxel, and is therefore an important treatment option.
1 A Voters: 43
Yes: 91% (39)
Abstain: 5% (2)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; CT, chemotherapy.
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unselected TN-ABC population docetaxel and carboplatin seem
to have a similar efficacy [48], although the study was not de-
signed as a non-inferiority study. Of note, in this study, 15% of
patients had no prior adjuvant chemotherapy and only 35% had
received (neo)adjuvant taxanes. Importantly, due to the signifi-
cantly better toxicity profile of carboplatin, it remains an at-
tractive treatment choice even for unselected TN-ABC patients.
Unfortunately, other putative predictive factors of increased
sensitivity to platinum, such as homologous recombination def-
icit (HRD) and the basal-like Prosigna PAM50 signature were
not proven of value for making treatment decisions in this
setting.
The future of TN-ABC treatment seems to lie in a better biolo-
gical characterization of this breast cancer subtype into further
subgroups, followed by the development of specific therapies for
each of the subgroups. An example is the Luminal AR subtype,
characterized by the expression of the androgen receptor; antian-
drogens have recently demonstrated some activity and are being
further evaluated, and where a potential predictive marker, the
Predict AR assay, is also being tested [49, 50].
Other recommendations
Several options exist for chemotherapy both for first and subsequent
lines of therapy. The ABC panel maintains that for patients pre-
treated with anthracyclines and taxanes the preferred agents, based
on their efficacy and toxicity profile, are capecitabine, vinorelbine
and eribulin. The latter is one of the few agents to provide a survival
gain, albeit small (2.5 months) in a heavily pretreated population of
ABC patients [51]. In a head-to-head comparison between eribulin
and capecitabine, as first or second line therapy, there were no major
differences between the drugs in efficacy but a different toxicity pro-
file [52].
It is also possible to re-challenge with anthracyclines, particu-
larly if there has been at least 1 year of disease-free survival, and if
the cumulative dose has not been reached, a common situation
nowadays because of the lower doses of anthracyclines used in
the adjuvant setting. Re-challenge with taxanes is also possible,
provided that there has been at least 1 year of disease-free
survival.
Another very attractive option is the use of metronomic
chemotherapy, defined as the use of low doses and short intervals,
which has been evaluated in the advanced setting with interesting
efficacy results and an excellent toxicity profile [53]. The best
evaluated regimen is oral cyclophosphamide and oral methotrex-
ate but other agents are being studied such as vinorelbine and
capecitabine.
In view of the lack of substantial efficacy differences among the
different available options, their toxicity profile must be discussed
with the patient and her/his preferences taken into account.
ABC3 also further endorsed the use of bone-modifying
agents (bisphosphonate, denosumab) in combination with
SECTION 6. OTHER RECOMMENDATIONS
GUIDELINE STATEMENT LoE Consensus
CHEMOTHERAPY OTHER
Metronomic chemotherapy is a reasonable treatment option, for patients not requiring rapid tumor re-
sponse. The better studied regimen is CM (low dose oral cyclophosphamide and methotrexate); other regi-
mens are being evaluated (including capecitabine and vinorelbine). Randomized trials are needed to
accurately compare metronomic CT with standard dosing regimens.
1 B Voters: 43
Yes: 88% (38)
Abstain: 5% (2)
Even if given in the adjuvant setting, provided that cumulative dose has not been achieved and that there are
no cardiac contra-indications, anthracyclines can be re-used in MBC, particularly if there has been at least
1 year of disease-free survival.
1 C Voters: 44
Yes: 93% (41)
Abstain: 5% (2)
BRCA-ASSOCIATED ABC
In patients with BRCA-associated triple negative or endocrine-resistant MBC previously treated with an
anthracycline with or without a taxane (in the adjuvant and/or metastatic setting), a platinum regimen is
the preferred option, if not previously administered and no suitable clinical trial is available.
1 A Voters: 44
Yes: 86% (38)
Abstain: 9% (4)
In patients with TN or Luminal MBC, genetic counseling and possibly BRCA testing should be discussed
with the patient, if the results can impact on treatment decisions and/or on clinical trials entry.
Expert Opinion Voters: 43
Yes: 91% (39)
Abstain: 7% (3)
BONE METASTASES
A bone modifying agent (bisphosphonate, denosumab) should be routinely used in combination with other
systemic therapy in patients with MBC and bone metastases.
Three-monthly zolendronic acid seems to be not inferior to standard monthly schedule.
Supplementation of calcium and vitamin D3 is mandatory, unless contraindications exist.
1 A
1 B
1 C
Voters: 44
Yes: 95% (42)
Abstain: 5% (2)
OTHERÅBIOMARKERS
Multigene panels, such as those obtained using next generation sequencing (NGS) or other technology, re-
garding evolving molecular changes in ABC tumors has not yet proven beneﬁcial in clinical trials, their im-
pact on outcome remains undeﬁned and should only be considered investigational.
1 C Voters: 44
Yes: 95% (42)
Abstain: 5% (2)
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; MBC, metastatic breast cancer.
Annals of Oncology Special article
Volume 28 | Issue 1 | 2017 doi:10.1093/annonc/mdw544 | 29
Downloaded from https://academic.oup.com/annonc/article-abstract/28/1/16/2660178
by Divisione Coordinamento Biblioteche Milano user
on 31 July 2018
calciumþ vitamin D3 supplementation as a routine component of
management of patients with bone metastases. Denosumab has
demonstrated slightly better efficacy and better tolerability, com-
pared to zoledronic acid [54], having the advantage of a subcutane-
ous route of administration and the disadvantage of a substantially
higher cost in most countries; where available, it can be considered a
preferred option. Currently available data support replacing routine
4 weekly administration of intravenous bisphosphonates by 3-
monthly zoledronic acid after an initial period of monthly use [55,
56]. Early 3-monthly use seems associated with increased need for
major surgeries [57], so a reasonable compromise may be to start
with the monthly schedule for the first year and then change to 3-
monthly regimen. No data exist on the optimal overall treatment
duration of bone modifying agents, and their efficacy must be
SECTION 7. SUPPORTIVE AND PALLIATIVE CARE
GUIDELINE STATEMENT LoE Consensus
Management of CANCER RELATED FATIGUE
Cancer related fatigue is frequently experienced by patients with ABC, exerts a deleterious impact on QoL and
limits physical, functional, psychological and social well-being. The etiology of this fatigue is complex so effect-
ive management needs to be multidimensional. It is important to assess it using appropriate PRO measures
before implementing various non-pharmacological (such as exercise—LoE: 1 A) and if needed pharmaco-
logical interventions (LoE: 2 B).
as in the text
100%
Management of CDK Inhibitor Induced Neutropenia
Neutropenia is the most common toxicity associated with CDK 4/6 inhibition and is not generally associated
with febrile neutropenia although an increase in infections has been reported. Treatment should be delayed
until neutrophils have recovered to at least 1000/ll; dose reduction can also be considered.
2 A 100%
Management of Non-Infectious Pneumonitis (NIP)
NIP is an uncommon complication of mTOR inhibition. Patient education is critical to ensure early reporting of
respiratory symptoms.
Treatment interruption and dose reduction are generally effective for grade 2 symptomatic NIP with use of sys-
temic steroids and treatment discontinuation for grade 3 or greater toxicity.
2 A 100%
Management of MUCOSITIS/STOMATITIS
Mild toothpaste and gentle hygiene are recommended for the treatment of stomatitis. Early intervention is rec-
ommended. For grade 2 or higher stomatitis, delaying treatment until the toxicity resolves and considering
lowering the dose of the targeted agent are also recommended. Consider adding steroid dental paste to treat
developing ulcerations.
Steroid mouthwash can be used for prevention of stomatitis (suggested schedule: 0.5mg/5ml dexamethasone,
10 ml to swish2 min then spit out qid).
Expert opinion
1 B
100%
Management of DYSPNEA
Treatable causes like pleural effusion, pulmonary emboli, cardiac insufﬁciency, anemia or drug toxicity must be
ruled out. Patient support is essential. Oxygen is of no use in non-hypoxic patients. Opioids are the drugs of
choice in the palliation of dyspnea (LoE: 1 A). Benzodiazepines can be used in patients experiencing anxiety
(LoE: 2A). Steroids can be effective in dyspnea caused by lymphangitis carcinomatosis, radiation or drug-
induced pneumonitis, superior vena cava syndrome, an inﬂammatory component, or in (cancer-induced) ob-
struction of the airways (in which case laser/stent is to be considered).
1 A,
2 A,
Expert opinion
100%
Management of NAUSEA and VOMITING
ESMO/MASCC GUIDELINES are available for management of chemotherapy-induced and morphine-induced
nausea and vomiting, and these are endorsed by ABC3.
There is a need to study nausea and vomiting related to chronic use of anticancer drugs. Expert Opinion 100%
Management of endocrine toxicities of mTOR inhibition
Hyperglycemia and hyperlipidemia are common sub-acute complications of mTOR inhibition. Evaluation of
preexisting diabetes or hyperglycemia at baseline is essential. Regular careful monitoring of glycemia and lipid
panel is needed to identify these toxicities.
Management of grade 1 and 2 hyperglycemia include treatment with oral antidiabetics and basal insulin, in ac-
cordance with international recommendation for diabetes mellitus treatment. Statins are indicated to treat
grade 2 and 3 hypercholesterolemia, and ﬁbrates should be introduced if triglyceride level >500mg/dl (with
attention to possible drug–drug interaction between everolimus and ﬁbrates). Treatment interruption and
dose reduction are generally effective for grade 2 and 3. Treatment should be discontinued for grade 4
toxicity.
2 A 100%
LoE, available level of evidence; consensus, percentage of panel members in agreement with the statement; QoL, quality of life.
NOTE: The statements of this section were not voted during the ABC Consensus panel but were developed and agreed upon by email, by all
panel members.
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weighed against long-term toxicity (such as osteonecrosis of the jaw
and atypical fractures).
When a bone modifying agent is given, supplements of calcium
and vitamin D are mandatory, except in the presence of contra-
indications.
Unfortunately, no multigene testing technology has been proven
to be beneficial in supporting treatment choices in ABC patients
[18] and the panel strongly discourages their use in clinical prac-
tice. They should continue to be considered investigational.
Supportive and palliative care
The ABC panel decided to dedicate several recommendations to
the management of disease and treatment-related symptoms, a
problem faced daily by patients and every practicing oncologist,
that can significantly affect a patient’s quality of life
Unfortunately, little high-quality data exist in many areas of
symptom management, probably due to difficulties in conduct-
ing research in this field, including the lack of well-defined end-
points, of patient-reported symptoms and side effects, and of
optimal tools to evaluate impact on quality of life for advanced
cancer patients. New classes of drugs introduced into breast can-
cer management have brought into the clinical practice new tox-
icities, poorly understood in the beginning and unfamiliar to
most oncologists. Undoubtedly this is an area of unmet need,
which should be a research priority.
The ABC3 guidelines provide guidance on the management of
drug-induced pneumonitis, mucositis [58, 59], endocrine and
metabolic disorders and CDK4/6 inhibitor-related neutropenia.
For nausea and vomiting ABC fully endorses the guidelines de-
veloped by ESMO/MASCC [60].
The ABC panel continues to discuss and provide guidance on
the management of frequent and difficult to manage cancer-
associated symptoms. In this edition, dyspnea and fatigue were
discussed. Cancer related fatigue is frequently experienced by
advanced cancer patients, exerts a deleterious impact on their
quality of life and limits physical, functional, psychological and
social well-being. Its etiology is complex and therefore effective
management needs to be multidimensional [61–63]. It is import-
ant to assess cancer related fatigue using appropriate patient-
reported outcome measures before implementing various
pharmacological and non-pharmacological interventions.
Randomized studies have suggested improvement of fatigue by
various types of exercise quite convincingly [64], and meditation
and some pharmacologic interventions are under evaluation. The
use of good evidence-based algorithms for management of cancer
related fatigue can also be helpful [65].
Conclusions
Since the ABC3 Conference two important initiatives have al-
ready been initiated.
The ESMO Magnitude of Clinical Benefit Scale (MCBS) [8]
has been published and is being applied to all new anticancer
treatments approved by EMA. The latest drug for which EMA
started the approval process was Palbociclib in September 2016
and its MCBS evaluation is included in the present article. Should
another agent be approved before the next ABC Consensus
Conference, the ESMO Committees will apply the MCBS and the
result will be made available as an e-update to the present
guidelines.
Following on the success of the ABC Consensus Conference,
the ABC community has come together to create the ABC Global
Alliance. This Alliance will function as a platform where all
involved partners (advocacy groups, pharma, cooperative
groups, societies, individuals) will be able to work together, in
projects designed to improve the lives of ABC patients. The
Global Status of ABC Decade Report [2] has highlighted several
areas of unmet needs. Based on these findings, a global Call-To-
Action is being developed, with tangible objectives that need to
be achieved within the next decade to meaningfully impact the
outcomes of ABC patients.
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